AKTS · NASDAQ
Aktis Oncology (AKTS) Stock Price & Fundamentals
Aktis Oncology (AKTS) closed at $497.52 on Oct 9, 2026, up 1.55% from the previous close of $489.91.
Share price, past year
1Y +30.82%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $497.52 |
| Sep 30, 2026 | $477.16 |
| Aug 31, 2026 | $443.99 |
| Jul 31, 2026 | $453.27 |
| Jun 30, 2026 | $440.76 |
| May 29, 2026 | $439.76 |
| Apr 30, 2026 | $436.48 |
| Mar 31, 2026 | $449.55 |
| Feb 27, 2026 | $412.23 |
| Jan 30, 2026 | $420.86 |
| Dec 31, 2025 | $399.67 |
| Nov 28, 2025 | $396.05 |
| Oct 31, 2025 | $386.36 |
Key statistics
- Market cap
- $26.59B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 53.4M
- Dividend yield
- —
- 52-week range
- $376.11 – $497.52
Aktis Oncology's market cap is $26.59B, based on a share price of $497.52 and 53.4M shares outstanding as of Jun 30, 2026.
Financials
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $3.38M | −$24.14M | −$0.44 |
| Q1 FY2026ended Mar 31, 2026 | $3.23M | −$18.33M | −$0.38 |
| Q2 FY2025ended Jun 30, 2025 | $1.60M | −$18.08M | −$22.39 |
| Q1 FY2025ended Mar 31, 2025 | $1.45M | −$14.99M | −$18.60 |
Company profile
- Name
- Aktis Oncology, Inc.
- Ticker
- AKTS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 17 Drydock Avenue, Suite #17-401, Boston, MA 02210
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0002035832
Recent SEC filings
- Aug 13, 2026
- Aug 13, 2026
- May 11, 2026
- May 11, 2026
- Apr 16, 2026
- Mar 30, 2026
- Mar 30, 2026
- Jan 12, 2026
Frequently asked questions
What is Aktis Oncology's stock price?
Aktis Oncology (AKTS) closed at $497.52 on Oct 9, 2026, up 1.55% from the previous close of $489.91.
What is Aktis Oncology's market cap?
Aktis Oncology's market cap is $26.59B, based on a share price of $497.52 and 53.4M shares outstanding as of Jun 30, 2026.
Sources and methodology
Fundamentals come from Aktis Oncology, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures